Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition comprising anaerobically cultivated human intestinal microbiota

A technology of intestinal microorganisms and anaerobic culture, applied in the field of composition application, can solve the problems of time-consuming, expensive, ugly, etc.

Inactive Publication Date: 2014-06-11
QUANTUM PHARMA
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This screening is time-consuming and costly
Further, this type of treatment is considered by many to be extremely ugly

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0104] The microbiota according to the invention were obtained from stool samples from a healthy single donor before 1995. Both the donor and the stool were carefully examined. The functional status of the gut microbiota of the donors was found to have normal functional values ​​for coprosterol, urobilin, mucin, fecal trypsin activity, short-chain fatty acids, and β-aspartylglycine. Tests for hepatitis A virus, hepatitis B virus, hepatitis C virus, cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus (HIV), calicivirus, and rotavirus were all negative. In addition, stool was screened for the presence of Salmonella, Shigella, Campylobacter, Yersinia, Clostridium difficile, and protozoan cysts, and all of these investigations were negative.

[0105] Feces samples (Bristo standard type 2) from the inside of the defecation sample were taken from the above-mentioned healthy donors, and immediately suspended in 30 ml of pre-reduced sterile bacteriological peptone-based...

Embodiment 2

[0143] Fresh or frozen stool samples from individuals not exposed to antibiotics or antibiotic resistance genes (for example, by bacterial infection) were inoculated under anaerobic conditions in 30 ml peptone yeast medium (Difco, USA), which The medium includes animal-derived cholesterol (for example, 1.25% freeze-dried hen egg yolk, Fresenius-Kabi, Sweden), and resazurin as an anaerobic indicator. The composition was re-cultured every two weeks. The bacterial content of the cultured product should be greater than 10 per milliliter of culture medium 6 , preferably greater than 10 9 indivual. The composition can be stored at -70°C after adding 10% glycerol.

Embodiment 3

[0145] A group of 32 patients aged 27-94 years (20 females, median age 78 years; 12 males, median age 75 years) was treated with the composition according to the invention. Of these patients, 22 had underlying chronic diseases such as cancer (breast, colon, prostate) and cardiovascular or lung disease. When recurrent Clostridium difficile infection (RCDI) was first detected, 11 patients took cephalosporin, 9 patients took clindamycin, 4 patients took ciprofloxacin, 2 patients Isoxazole was given to penicillin, 3 other patients were given certain other antibiotics, and finally, 1 patient was given azithromycin. Before receiving the composition according to the invention, 2 patients were not pretreated with specific antibiotics.

[0146] Conventionally, a volume of 30 ml of the invention according to Example 1 is administered rectally via a transrectal catheter in the sigmoid colon or via a colonoscope. Clostridial toxin analysis was performed according to general practice at ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an anaerobic micro-ecological system, a composition comprising an aerobically cultivated human intestinal microbiota for the treatment or prophylaxis of diseases, and wherein the microbiota in the composition have not been exposed to antibiotics used after 1995. The present invention further relates to the use of the composition for the prevention and treatment of disease and a method for preparing the composition.

Description

technical field [0001] The present invention relates to anaerobic micro-ecosystems comprising anaerobically cultured human gut microbiota. The present invention also relates to compositions of anaerobically cultured microbiota constituting a functional inoculum for renormalizing a disrupted human microbiome and gastrointestinal function. [0002] The invention further relates to the use of the composition for the prophylaxis and treatment of diseases and methods for the preparation of the composition. Background technique [0003] The gastrointestinal microbiota (microbiota) consists of several complex microecosystems in which interactions between individual microbial strains and between microbiota and host occur. Interaction with the host occurs through direct contact with the mucosal wall and indirectly (eg, through metabolites and signaling substances). [0004] The homeostasis of the gut can be disturbed by external and internal physical, chemical, and biological facto...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A61P1/12A61P1/00A61P17/10A61P19/02A61P35/00
CPCA61K2035/11A61K35/74A61P1/00A61P1/04A61P1/12A61P17/10A61P19/02A61P35/00Y02A50/30
Inventor 阿诺德·伯斯泰德托尔·米德威迪特伊丽莎白·诺林彼得·本诺阿蒂拉·达尔格林
Owner QUANTUM PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products